Does nitroglycerin improve survival outcomes in patients with acute coronary syndrome?

Nitroglycerin Does Not Improve Survival in ACS

Nitroglycerin should be used for symptomatic relief of anginal pain in hemodynamically stable ACS patients, but it has not been shown to improve survival outcomes. 1, 2

Key Evidence on Survival

The most recent 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines explicitly state that "analgesic therapies may provide symptomatic relief, but they have not been shown to improve clinical outcomes in patients with ACS" 2. This represents the highest quality evidence available and directly addresses the survival question.

Historical Context vs. Current Evidence

While older meta-analyses from the 1990s suggested potential mortality benefits:

• A 1992 meta-analysis of 7 IV nitroglycerin trials showed 48% reduction in odds of death (12.5% vs 20% mortality) 3
• A 1991 single-center study of 310 patients reported fewer deaths at 1 year with IV nitroglycerin 4

However, these older studies have not been validated in modern ACS management, which includes routine early revascularization, dual antiplatelet therapy, and contemporary medical therapy. The 2025 guidelines do not recommend nitroglycerin for mortality reduction.

Appropriate Clinical Use

Nitroglycerin remains indicated for:

Sublingual Administration

• 0.3-0.4 mg every 5 minutes up to 3 doses total
• Use only in hemodynamically stable patients with SBP ≥90 mmHg
• Provides symptomatic relief of anginal pain 1, 2

IV Administration

• Start at 10 μg/min and titrate to pain relief
• Consider for:
  • Persistent anginal pain after sublingual nitrates
  • ACS with hypertension
  • ACS with pulmonary edema 1, 2

Critical Contraindications and Pitfalls

Absolute contraindications:

• SBP <90 mmHg or drop >30 mmHg below baseline
• Suspected right ventricular infarction
• Recent phosphodiesterase-5 inhibitor use:
  • Within 12 hours of avanafil
  • Within 24 hours of sildenafil/vardenafil
  • Within 48 hours of tadalafil 1, 2

Important warnings from FDA labeling:

• Severe hypotension and shock can occur with even small doses 5
• May cause paradoxical bradycardia and increased angina 5
• Tachyphylaxis develops after approximately 24 hours of continuous use 1, 5
• May interfere with heparin anticoagulation—monitor aPTT frequently 5

Recent Prehospital Data

A 2026 nationwide "target trial emulation" study of 70,890 patients found no significant reduction in adverse prehospital outcomes (CPR, defibrillation, cardioversion, antiarrhythmics, or pacing) with prehospital nitroglycerin administration 6. This reinforces that nitroglycerin's role is symptomatic, not prognostic.

Bottom Line Algorithm

For ACS patients:

1. Check SBP—must be ≥90 mmHg
2. Rule out RV infarction (especially inferior STEMI with hypotension)
3. Verify no recent PDE5 inhibitor use
4. If criteria met → Give for pain relief only
5. Do not expect or rely on mortality benefit
6. Prioritize proven mortality-reducing therapies: aspirin, P2Y12 inhibitors, early revascularization, and guideline-directed medical therapy